Skip to main content

CITADEL ADVISORS LLC

Position in LXEO — Lexeo Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Position in LXEO

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$22,012,893
-$15,466,074 QoQ
Shares Held
3,834,999
+1.6% QoQ
Ownership
4.88%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in LXEO Over Time

Shares Held

Position Value (USD)

Derivatives in LXEO

reported options exposure · as of Mar 31, 2026
CallValue
$61,418
CallShares
10,700
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. LXEO ranks #58 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in LXEO

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $22,012,893 3,834,999
2026-03-31 $61,418 10,700
2025-12-31 $37,478,967 3,774,317
2025-09-30 $24,694,444 3,719,043
2025-06-30 $21,443,130 5,334,112
2025-06-30 $14,504,027 3,607,967
2025-03-31 $44,416 12,800
2025-03-31 $9,450,069 2,723,363
2025-03-31 $347 100
2024-12-31 $17,919,728 2,723,363
2024-09-30 $24,619,201 2,723,363
2024-06-30 $41,040,120 2,558,611
2024-03-31 $39,246,741 2,502,981
2023-12-31 $27,970,567 2,084,245